Released : February 03, 2021 16:36 RNS Number : 9191N MaxCyte, Inc. 03 February 2021 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (OR TO ANY US PERSON), CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY
Released : January 20, 2021 07:00 RNS Number : 2360M MaxCyte, Inc. 20 January 2021 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update · Full-year revenues at $26.2m (21% growth over FY 2019) and second half revenue at $15.3m (15% over
Released : December 23, 2020 07:00 RNS Number : 6024J MaxCyte, Inc. 23 December 2020 TRADING UPDATE MaxCyte to exceed 2020 Full Year market expectations Gaithersburg, Maryland - 23 December 2020: MaxCyte (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today
Released : October 01, 2020 07:00 RNS Number : 6925A MaxCyte, Inc. 01 October 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") Director Dealings Maryland, USA - 1 October 2020 : MaxCyte (LSE: MXCT, MXCS ), the global cell-based medicines and life sciences company, announces that J.
Released : September 21, 2020 07:00 RNS Number : 5084Z MaxCyte, Inc. 21 September 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") Results for the Six Months ended 30 June 2020 · Strong revenue growth of 30%, generating positive EBITDA (before CARMA investment) · Significant
Released : September 10, 2020 13:42 RNS Number : 6540Y MaxCyte, Inc. 10 September 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of options Gaithersburg, Maryland - 10 September 2020: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company,
Released : July 16, 2020 18:04 RNS Number : 2766T MaxCyte, Inc. 16 July 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") Director Dealings and Issue of Equity Gaithersburg, Maryland - 16 July 2020: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company,
Released : July 15, 2020 07:00 RNS Number : 0040T MaxCyte, Inc. 15 July 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update · First-half revenues at $10.9m delivering growth of 30% year-on-year · Launch of expanded new ExPERT ™ range of disposables to broaden
Released : July 01, 2020 07:00 RNS Number : 5842R MaxCyte, Inc. 01 July 2020 SCHEDULE 6 AIM BLOCK ADMISSION RETURN / TOTAL VOTING RIGHTS Please ensure the entries on this return are typed a. Name of company MaxCyte, Inc. b. Name of scheme(s) MaxCyte Long Term Incentive Plan c.
Released : May 21, 2020 13:50 RNS Number : 6557N MaxCyte, Inc. 21 May 2020 THIS ANNOUNCEMENT IS RESTRICTED AND NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (OR TO ANY US PERSON), CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC
